ALLR (38) DARE (44) OPTH (49) RKTO (44) ⌘ Pro Terminal →

Biofrontera Inc. (BFRI) — RQD Stock Rating Cockpit

$0.93 +5.09% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Biofrontera Inc. (BFRI) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $13.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BFRI)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

42.230 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE34% OF RANGE

L: $1$0.93H: $2

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on BFRI

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (20)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (40)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (47)

17/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like BFRI

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BFRI)

✓Walkthrough of BFRI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BFRI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.89%📐 HORIZONTAL RANGE

2026-10-30O $0.94H $0.94L $0.85C $0.93VOL 281.9K

RES: $1.87SUP: $0.77SMA50: $1.15SMA200: $1.03

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BFRI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BFRI Butterfly Map → + Track BFRI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +11.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BFRI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BFRI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BFRI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BFRI)

Health Care Rank #651 of 1016 ⚔️ ALLR vs BFRI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BFRI vs. ALLR, DARE, OPTH, RKTO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Biofrontera Inc. (BFRI) ranks #651 by composite RQD confidence (40/100, grade D-) and #865 by equity capitalization ($13.8M). Within this direct 5-issuer industry benchmark cohort, BFRI leads on earnings valuation at N/A trailing P/E, while BFRI leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OPTH currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with BFRI at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BFRI ACTIVE Biofrontera Inc.	D-	40/100	—	—	-35.0%	+5.09%	$13.8M	Benchmark Subject
ALLR Allarity Therapeutics Inc.	D-	38/100	—	—	-35.0%	-6.32%	$14.2M	/allr-vs-bfri →
DARE Dare Bioscience Inc.	D	44/100	—	71.3%	-35.0%	+0.22%	$13.4M	/dare-vs-bfri →
OPTH Optimi Health Corp.	D	49/100	—	—	—	-6.81%	$14.9M	/opth-vs-bfri →
RKTO Rocket One Inc.	D	44/100	—	—	-35.0%	-4.96%	$12.8M	/rkto-vs-bfri →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001858685

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Biofrontera Inc. (BFRI) reported GAAP revenue of $41.7M (+11.7% vs. FY2024 revenue of $37.3M , and +22.4% cumulative change since FY2023) , GAAP net income of -$10.5M, operating cash flow of -$13.4M, and free cash flow of -$13.4M (-30.0% YoY). On the balance sheet, BFRI closed FY2025 with $28.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$41.7M	-$10.5M	-$13.4M	-$13.4M	$28.6M	—
FY2024 (FY)	2024-12-31	$37.3M	-$17.8M	-$10.3M	-$10.3M	$22.1M	—
FY2023 (FY)	2023-12-31	$34.1M	-$20.1M	-$24.9M	-$24.9M	—	—

3. BFRI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BFRI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Biofrontera Inc. (NASDAQ: BFRI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.93 (+5.09% 1D, market cap $13.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BFRI ranks #651 in composite RQD confidence.

How does BFRI compare to ALLR and DARE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BFRI carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALLR (Allarity Therapeutics Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $14.2M) and DARE (Dare Bioscience Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $13.4M). Among the 5-stock peer group, BFRI leads on earnings multiple (N/A) while BFRI leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BFRI?

Per BFRI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001858685), Biofrontera Inc. generated $41.7M in revenue (+11.7% YoY), -$10.5M in net income, and -$13.4M in free cash flow against $28.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BFRI trading relative to its 50-day, 200-day, and 52-week technical levels?

BFRI last traded at $0.93 (+5.09% on volume of 148,663 shares), positioning the stock -19.13% below its 50-day simple moving average ($1.15) and -9.71% below its 200-day simple moving average ($1.03). Across its 52-week range of $0.56 to $1.66, BFRI sits at the 33.6% percentile with a 14-day RSI of 42.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.05).

BFRI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell BFRI stock right now?

Biofrontera Inc. (BFRI) currently earns a Roarable Rating of D- (Sell — SELL) with 40/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is BFRI's 12-month price target and RQD AI Jury consensus?

BFRI's 12-month base price target is $0.85 (range $0.66 to $1.74), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: BFRI RQD Cockpit BFRI 12M Forecast BFRI Earnings & Move BFRI Dividends & DRIP BFRI Insiders & 13F BFRI Whale Options BFRI Profit Sankey BFRI News & Why